Synergistic activity of antifungal drugs and lipopeptide AC7 against <em>Candida albicans</em> biofilm on silicone

Chiara Ceresa; Maurizio Rinaldi; Letizia Fracchia; Chiara Ceresa; Maurizio Rinaldi; Letizia Fracchia

doi:10.3934/bioeng.2017.2.318

AIMS Bioengineering

2017, Volume 4, Issue 2: 318-334. doi: 10.3934/bioeng.2017.2.318

Previous Article Next Article

Research article Topical Sections

Synergistic activity of antifungal drugs and lipopeptide AC7 against Candida albicans biofilm on silicone

Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Largo Donegani 2, 28100 Novara, Italy

Received: 30 January 2017 Accepted: 12 April 2017 Published: 19 April 2017

The occurrence of Candida albicans device-associated infections is tightly correlated to the ability of this fungus to form biofilms. The presence of this three-dimensional structure protects cells from host defenses, and significantly increases their resistance to antifungal agents. Lipopeptide biosurfactants are microbial products with interesting antibacterial, antifungal and anti-adhesive properties. Aim of the present study was to investigate a possible synergistic effect of lipopeptide AC7BS in combination with amphotericin B or fluconazole against C. albicans planktonic cells, biofilm formation and 24 h-old biofilms on medical-grade silicone elastomer disks, in simulated physiological conditions. In co-incubation experiments, AC7BS alone was not effective. However, the combination of AC7BS with the antifungal compounds resulted in a synergistic increase in the efficacy of the drugs against planktonic cells and biofilm, leading to a reduction of MICs and SMICs₅₀. In pre-coating conditions, amphotericin B alone and AC7BS alone significantly inhibited C. albicans biofilms. When the two molecules were tested in association, a synergistic effect was observed on different phases of biofilm formation and a lower SMIC₅₀was detected. The observed synergism could be related to the combination of the AC7BS anti-adhesive activity and the AMB antifungal effect, but also to the ability of the biosurfactant to affect membranes, thus facilitating AMB entry in the cells. These results suggest that AC7BS can be considered a potential inhibitor of C. albicans biofilm on medical insertional materials and its use as coating agent may potentiate the effect of antifungal compounds such as AMB, when applied in combination.
- amphotericin,
- antifungals,
- biofilm,
- biosurfactant,
- Candida albicans,
- coating,
- fluconazole,
- lipopeptide,
- silicone elastomer,
- synergy
Citation: Chiara Ceresa, Maurizio Rinaldi, Letizia Fracchia. Synergistic activity of antifungal drugs and lipopeptide AC7 against Candida albicans biofilm on silicone[J]. AIMS Bioengineering, 2017, 4(2): 318-334. doi: 10.3934/bioeng.2017.2.318

Related Papers:

Abstract

The occurrence of Candida albicans device-associated infections is tightly correlated to the ability of this fungus to form biofilms. The presence of this three-dimensional structure protects cells from host defenses, and significantly increases their resistance to antifungal agents. Lipopeptide biosurfactants are microbial products with interesting antibacterial, antifungal and anti-adhesive properties. Aim of the present study was to investigate a possible synergistic effect of lipopeptide AC7BS in combination with amphotericin B or fluconazole against C. albicans planktonic cells, biofilm formation and 24 h-old biofilms on medical-grade silicone elastomer disks, in simulated physiological conditions. In co-incubation experiments, AC7BS alone was not effective. However, the combination of AC7BS with the antifungal compounds resulted in a synergistic increase in the efficacy of the drugs against planktonic cells and biofilm, leading to a reduction of MICs and SMICs₅₀. In pre-coating conditions, amphotericin B alone and AC7BS alone significantly inhibited C. albicans biofilms. When the two molecules were tested in association, a synergistic effect was observed on different phases of biofilm formation and a lower SMIC₅₀was detected. The observed synergism could be related to the combination of the AC7BS anti-adhesive activity and the AMB antifungal effect, but also to the ability of the biosurfactant to affect membranes, thus facilitating AMB entry in the cells. These results suggest that AC7BS can be considered a potential inhibitor of C. albicans biofilm on medical insertional materials and its use as coating agent may potentiate the effect of antifungal compounds such as AMB, when applied in combination.

References

[1]	Francolini I, Donelli G (2010) Prevention and control of biofilm-based medical-device-related infections. Fems Immunol Med Mic 59: 227–238. doi: 10.1111/j.1574-695X.2010.00665.x
[2]	Fanning S, Mitchell AP (2012) Fungal bioﬁlms. Plos Pathog, DOI:10.1371/journal.ppat.1002585.
[3]	Lazzell AL, Chaturvedi AK, Pierce CG, et al. (2009) Treatment and prevention of Candida albicans bioﬁlms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemot 64: 567–570. doi: 10.1093/jac/dkp242
[4]	Sardi JC, Scorzoni L, Bernardi T, et al. (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62: 10–24. doi: 10.1099/jmm.0.045054-0
[5]	Ramage G, Martınez P, Lopez RJL (2006) Candida biofilms on implanted biomaterials: a clinically significant problem. Fems Yeast Res 6: 979–986. doi: 10.1111/j.1567-1364.2006.00117.x
[6]	Dominic RM, Shenoy S, Baliga S (2007) Candida biofilms in medical devices: evolving trends. Kathmandu Univ Med J 5: 431–436.
[7]	Gow NA, van de Veerdonk FL, Brown AJ, et al. (2012) Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 10: 112–122.
[8]	Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1–53. doi: 10.3109/10408410903241444
[9]	Mayer FL, Wilson D, Hube B (2013) Candida albicans pathogenicity mechanisms. Virulence 4: 119–128. doi: 10.4161/viru.22913
[10]	Ramage G, Rajendran R, Sherry L (2012) Fungal biofilm resistance. Int J Microbiol 2012: 1–14.
[11]	Kojic EM, Darouiche RO (2004) Candida infections on medical devices. Clin Microbiol Rev 17: 255–267. doi: 10.1128/CMR.17.2.255-267.2004
[12]	Fracchia L, Banat JJ, Cavallo M, et al. (2015) Potential therapeutic applications of microbial surface-active compounds. AIMS Bioeng 2: 144–162. doi: 10.3934/bioeng.2015.3.144
[13]	Ceresa C, Rinaldi M, Chiono V, et al. (2016) Lipopeptides from Bacillus subtilis AC7 inhibit adhesion and bioﬁlm formation of Candida albicans on silicone. Anton Van Leeuw 109: 1375–1388. doi: 10.1007/s10482-016-0736-z
[14]	Rivardo F, Martinotti MG, Turner RJ, et al. (2011) Synergistic effect of lipopeptide biosurfactant with antibiotics against Escherichia coli CFT073 bioﬁlm. Int J Antimicrob Ag 37: 324–331. doi: 10.1016/j.ijantimicag.2010.12.011
[15]	Rivardo F, Martinotti MG, Turner RJ, et al. (2010) The activity of silver against Escherichia coli biofilm is increased by a lipopeptide biosurfactant. Can J Microbiol 56: 272–278. doi: 10.1139/W10-007
[16]	Rivardo F, Turner RJ, Allegrone G, et al. (2009) Anti-adhesion activity of two biosurfactants produced by Bacillus spp. prevents bioﬁlm formation of human bacterial pathogens. Appl Microbiol Biot 83: 541–553.
[17]	Busscher HJ, van Hoogmoed CG, Geertsema DGI, et al. (1997) Streptococcus thermophilus and its biosurfactants inhibit adhesion by Candida spp. on silicone rubber. Appl Environ Microb 63: 3810–3817.
[18]	Rodriguez TJL, Arendrup MC, Barchiesi F, et al. (2008) EUCAST deﬁnitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infec 14: 398–405.
[19]	Nweze EI, Ghannoum A, Chandra J, et al. (2012) Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida bioﬁlms. J Antimicrob Chemot 67: 149–153. doi: 10.1093/jac/dkr429
[20]	Martins N, Ferreira IC, Barros L, et al. (2014) Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia 177: 223–240. doi: 10.1007/s11046-014-9749-1
[21]	Hawser SP, Douglas LJ (1994) Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62: 915–921.
[22]	Ruhnke M, Hartwig K, Koﬂa G (2008) New options for treatment of candidaemia in critically ill patients. Clin Microbiol Infec 14: 46–54. doi: 10.1111/j.1469-0691.2008.01981.x
[23]	Lohner K (2014) Antimicrobial mechanisms: a sponge against fungal infections. Nat Chem Biol 10: 411–412. doi: 10.1038/nchembio.1518
[24]	Charlier C, Hart E, Lefort A, et al. (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemot 57: 384–410. doi: 10.1093/jac/dki473
[25]	Liu S, Hou Y, Chen X, et al. (2014) Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int J Antimicrob Ag 43: 395–402. doi: 10.1016/j.ijantimicag.2013.12.009
[26]	Bonmatin JM, Laprévote O, Peypoux F (2003) Diversity among microbial cyclic lipopeptides: iturins and surfactins. Activity–structure relationships to design new bioactive agents. Comb Chem High T Sc 6: 541–556.
[27]	Carrillo C, Teruel JA, Aranda FJ, et al. (2003) Molecular mechanism of membrane permeabilization by the peptide antibiotic surfactin. Biochim Biophys Acta 1611: 91–97. doi: 10.1016/S0005-2736(03)00029-4
[28]	Deleu M, Paquot M, Nylander T (2005) Fengycin interaction with lipid monolayers at the air-aqueous interface-implications for the effect of fengycin on biological membranes. J Colloid Interf Sci 283: 358–365. doi: 10.1016/j.jcis.2004.09.036
[29]	Deleu M, Paquot M, Nylander T (2008) Effect of fengycin, a lipopeptide produced by Bacillus subtilis, on model biomembranes. Biophys J 94: 2667–2679. doi: 10.1529/biophysj.107.114090
[30]	Eeman M, Berquand A, Dufrêne YF, et al. (2006) Penetration of surfactin into phospholipid monolayers: nanoscale interfacial organization. Langmuir 22: 11337–11345. doi: 10.1021/la061969p
[31]	Biniarz P, Baranowska G, Feder KJ, et al. (2015) The lipopeptides pseudofactin II and surfactin effectively decrease Candida albicans adhesion and hydrophobicity. Anton Van Leeuw 108: 343–353. doi: 10.1007/s10482-015-0486-3
[32]	Sriram MI, Kalishwaralal K, Deepak V, et al. (2011) Biofilm inhibition and antimicrobial action of lipopeptide biosurfactant produced by heavy metal tolerant strain Bacillus cereus NK1. Colloid Surface B 85: 174–181. doi: 10.1016/j.colsurfb.2011.02.026
[33]	Janek T, Łukaszewicz M, Krasowska A (2012) Anti-adhesive activity of the biosurfactant pseudofactin II secreted by the Arctic bacterium Pseudomonas fluorescens BD5. BMC Microbiol 12: 24. doi: 10.1186/1471-2180-12-24

Reader Comments

Your name:*

Email:*
© 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)